~~<i id='31DCEA1AE9'><strike id='31DCEA1AE9'><tt id='31DCEA1AE9'><pre id='31DCEA1AE9'></pre></tt></strike></i>~~

Home» leisure time» explore

explore

author：comprehensive 2025-10-06 12:10:51 Page View：18213

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virtual Event: March of the Biosimilars
Next article： Cancer drug shortages should be causing more outrage

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

The struggle to figure out which patients 'deserve' Wegovy

AdobeThereisjustnotenoughWegovy.Thecurrentmanufacturingshortagewilleventuallyend,andthosewhohaveheal

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Grad students accuse University of California of wage theft

UCSanDiegostudentsprotestedatanalumnieventinMay,wheretheyaccuseduniversityleadershipofwagetheft.Cour